InvestorsObserver
×
News Home

Is Arcturus Therapeutics Holdings Inc (ARCT) a Stock to Watch After Gaining 47.26% This Week?

Monday, November 20, 2023 12:02 PM | InvestorsObserver Analysts

Mentioned in this article

Is Arcturus Therapeutics Holdings Inc (ARCT) a Stock to Watch After Gaining 47.26% This Week?

Arcturus Therapeutics Holdings Inc (ARCT) stock is up 47.26% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Arcturus Therapeutics Holdings Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ARCT!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ARCT Stock Today?

Arcturus Therapeutics Holdings Inc (ARCT) stock is trading at $26.08 as of 11:49 AM on Monday, Nov 20, a rise of $1.09, or 4.34% from the previous closing price of $24.99. The stock has traded between $24.78 and $26.71 so far today. Volume today is light. So far 222,113 shares have traded compared to average volume of 412,602 shares.

More About Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19. Click Here to get the full Stock Report for Arcturus Therapeutics Holdings Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App